- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01546467
Cognitive Remediation in Early Phase Psychosis
March 1, 2012 updated by: Oslo University Hospital
The purpose of the study is to investigate the effect of a 30 hour cognitive remediation program for young patients with early phase schizophrenia spectrum disorders on cognitive, clinical and functional outcome measures.
The remediation program is integrated with whatever active rehabilitation the participant is currently attending (school, work, day program etc).
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
50
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Torill Ueland, PhD
- Phone Number: +47 22118370
- Email: torill.ueland@medisin.uio.no
Study Contact Backup
- Name: Ingrid Melle, PhD
- Phone Number: +47 22118469
- Email: ingrid.melle@medisin.uio.no
Study Locations
-
-
-
Oslo, Norway, 0407
- Recruiting
- Psychosis Research Unit, Division of Mental Health and Addiction, Oslo University Hospital.
-
Contact:
- Torill Ueland, PhD
- Phone Number: +47 22118370
- Email: torill.ueland@medisin.uio.no
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 40 years (ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Early phase schizophrenia, schizoaffective disorder, psychosis NOS
- Less than 5 years since start of adequate treatment for psychotic disorder
- Age between 18-40
- Norwegian speaking (sufficiently to understand and complete assessments)
Exclusion Criteria:
- Traumatic brain injury
- Neurological disorder as determined by medical history
- IQ below 70
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Cognitive remediation
30 hour computer based cognitive remediation integrated in participants current rehabilitation program (school, work, day program)
|
Cognitive remediation including feedback from neurocognitive assessment, psychoeducation about cognitive deficits, 30 hours of computer based drill and practise and strategy coaching based cognitive remediation, 1-3 collaborative meetings with cognitive specialist, participant, therapist and teacher, occupational therapist or other therapist (depending on participants rehabilitation situation) to enhance transfer of skills to daily functioning
|
NO_INTERVENTION: Wait list control group
Participant continues in treatment/rehabilitation program as usual until 9 month assessment when participant receives the same cognitive remediation program as the experimental group.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
MATRICS Consensus Cognitive Battery (MCCB)
Time Frame: Change in MCCB performance from baseline to 4 months and 9 months
|
Included in the MCCB are measures of the following cognitive domains: Speed of Processing, Attention, Working memory, Verbal learning, Visual Learning, Reasoning and problem solving and Social Cognition.
In addition the following tests are included: HVLT-R and BVMT-R delayed recall to measure memory, TMTB (Halstead Reitan) and Color Word Inteference Test (D-KEFS) to measure executive functioning), Digit span (WAIS-III)to measure working memory, Grooved Pegboard (Halstead Reitan) to measure motor function.
|
Change in MCCB performance from baseline to 4 months and 9 months
|
UCSD Performance Based Skilled Assessment Brief Version (UPSA-B)
Time Frame: Change in UPSA-B performance from baseline to 4 months and 9 months
|
Change in UPSA-B performance from baseline to 4 months and 9 months
|
|
Cognitive Assessment Interview (CAI)
Time Frame: Change in CAI scores from baseline to 4 months and 9 months
|
Change in CAI scores from baseline to 4 months and 9 months
|
|
Social Functioning Scale (SFS)
Time Frame: Change in SFS scores from baseline to 4 months and 9 months
|
Change in SFS scores from baseline to 4 months and 9 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Calgary Depression Scale
Time Frame: Change in CDS scores from baseline to 4 months and 9 months
|
Change in CDS scores from baseline to 4 months and 9 months
|
|
Global Assessment of Function (GAF)- split version
Time Frame: Change in GAF scores from baseline to 4 months and 9 months
|
Change in GAF scores from baseline to 4 months and 9 months
|
|
event related fMRI
Time Frame: Change in BOLD fMRI signal from baseline to 4 months
|
Event-related fMRI will be performed to measure neuronal activity during a spatial working memory tasks and an executive planning task.
All fMRI data will be collected on Ullevål's 3 T General Electric Sigma HDx scanner.
|
Change in BOLD fMRI signal from baseline to 4 months
|
Rosenberg Self-Esteem Scale (RSES)
Time Frame: Change in RSES scores from baseline to 4 months and 9 months
|
Change in RSES scores from baseline to 4 months and 9 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Torill Ueland, PhD, Psychosis Research Unit, Division of Mental Health and Addiction, Oslo University Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2009
Primary Completion (ANTICIPATED)
December 1, 2013
Study Completion (ANTICIPATED)
December 1, 2013
Study Registration Dates
First Submitted
January 12, 2012
First Submitted That Met QC Criteria
March 1, 2012
First Posted (ESTIMATE)
March 7, 2012
Study Record Updates
Last Update Posted (ESTIMATE)
March 7, 2012
Last Update Submitted That Met QC Criteria
March 1, 2012
Last Verified
March 1, 2012
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2010/1788 (REK)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schizophrenia
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Bradley LegaRecruiting
-
All India Institute of Medical Sciences, BhubaneswarRecruitingTreatment Resistant SchizophreniaIndia
-
King's College LondonSouth London and Maudsley NHS Foundation TrustRecruitingTreatment-resistant Schizophrenia | Healthy Controls | Treatment-responsive SchizophreniaUnited Kingdom
-
University of Sao PauloUnknownRefractory Schizophrenia | Super Refractory SchizophreniaBrazil
-
Ohio State UniversityRecruitingTreatment-resistant SchizophreniaUnited States
-
University Hospital, BrestRecruitingSchizophrenia | Schizophrenia Prodromal | Schizophrenia, ChildhoodFrance
-
NYU Langone HealthNot yet recruitingTreatment-resistant SchizophreniaUnited States
-
Johns Hopkins UniversityNational Institute of Mental Health (NIMH)RecruitingTreatment-resistant SchizophreniaUnited States
Clinical Trials on Cognitive remediation
-
Queen's UniversityCompleted
-
Queen's UniversityPfizerCompleted
-
Yale UniversityCompletedCancer | Cancer of the ProstateUnited States
-
Fundació Sant Joan de DéuCompletedIndication for Modification of Patient Cognitive StatusSpain
-
VA Office of Research and DevelopmentRecruiting
-
New York State Psychiatric InstituteNational Institute of Mental Health (NIMH); Columbia UniversityCompletedSchizophrenia | Schizoaffective DisorderUnited States
-
Queen's UniversityCompleted
-
Douglas Mental Health University InstituteMcGill University; Canadian Institutes of Health Research (CIHR)Recruiting
-
Gemma Garrido GarcíaCompleted
-
Institut BergoniéUniversity of Bordeaux; Association OncogiteRecruiting